Falciparum Malaria Infection in a Case of Sickle Cell Trait; Unbalancing the Balanced Polymorphism

Amale, Amar; Acharya, Sourya; Shukla, Samarth; Dubey, Sameeksha

doi:10.1007/s12288-012-0158-7

Cited by 2 publications

(2 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wasnik et al reported a study on evaluation of serum zinc and antioxidant vitamins in adolescent homozygous sickle cell patients in Wardha [20]. Other related studies were reviewed [21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcome and Laboratory Parameters in Sickle Cell Anemia Patients of Pediatric Age Group Post Hydroxyurea Therapy

Gupta

Hiwale

Vagha

et al. 2021

JPRI

View full text Add to dashboard Cite

Background: Homozygous condition in Sickle cell disease (SCD) is called as sickle cell anemia(SCA). In sickle cell anemia patients clinically presents as hemolytic anemia, vaso-occlusive events, along with organ dysfunction and acute chest syndrome. Recently Hydroxyurea has shown promising results in treatment of sickle cell anemia. Hydroxyurea is the only approved drug by FDA which has shown disease modifying results. Aim: To determine the clinical outcome and laboratory parameters in SCA patients of pediatric age group post-hydroxyurea therapy. Methods: A total of 30 patients who were diagnosed as Sickle cell anemia (SCA) patients in Sickle cell anemia OPD of Pediatric department were included in the study. Results: Hydroxyurea therapy is expected to increase HbF% levels and improve the clinical outcome and laboratory parameters in sickle cell anemia patients of pediatric age group.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Outcome and Laboratory Parameters in Sickle Cell Anemia Patients of Pediatric Age Group Post Hydroxyurea Therapy

Gupta

Hiwale

Vagha

et al. 2021

JPRI

View full text Add to dashboard Cite

show abstract

“…Some haemoglobinopathies affect the quality and structure of haemoglobin, such as sickle cell disease, while other haemoglobinopathies affect the quantity of haemoglobin present, such as thalassaemias. Haemoglobinopathies appear to have developed as a by-product protection mechanism against falciparum malaria, originating in Sub-Saharan Africa, the Arabian Peninsula and the Indian subcontinent (Amale et al 2013).…”

Section: Genetics and Screeningmentioning

confidence: 99%

Enhancing the care of patients with sickle cell disease

Blackmore

Taylor

2019

Nursing Standard

View full text Add to dashboard Cite

When typically round red blood cells intermittently elongate and become lodged in the body's microcirculation, this can result in painful vaso-occlusive crises, often referred to as 'sickle cell crises'. The sickling and unsickling process can result in acute pain, chronic anaemia, ischaemic injury and multiple organ damage. One of the main concerns raised by patients with sickle cell disease is the lack of knowledge and understanding of their condition among healthcare professionals in acute care settings. Therefore, this article aims to enhance nurses' understanding of sickle cell disease and the effective management of painful vaso-occlusive crises. While sickle cell disease was traditionally perceived to only occur in people of black African or African-Caribbean ethnic origin, this article seeks to challenge this belief and reconsider sickle cell as a public health concern for all.

show abstract

Falciparum Malaria Infection in a Case of Sickle Cell Trait; Unbalancing the Balanced Polymorphism

Abstract: Suffers of Sickle cell trait are protected against plasmodium falciparum malaria because of the law of balanced polymorphism. We present a case of sickle cell trait infected with severe falciparum malaria unbalancing of balanced polymorphism.

Cited by 2 publications

References 7 publications

Clinical Outcome and Laboratory Parameters in Sickle Cell Anemia Patients of Pediatric Age Group Post Hydroxyurea Therapy

Clinical Outcome and Laboratory Parameters in Sickle Cell Anemia Patients of Pediatric Age Group Post Hydroxyurea Therapy

Enhancing the care of patients with sickle cell disease

Contact Info

Product

Resources

About